Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

NCT03164928 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03164928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03164928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
May 7, 2018
Completion date
December 20, 2023
Enrollment
24 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

evaluate the safety and efficacy of denosumab in pediatric subjects with, glucocorticoid-induced osteoporosis